Capital Investment Advisors LLC Raises Stock Position in Zoetis Inc. (NYSE:ZTS)

Capital Investment Advisors LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 14.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,417 shares of the company’s stock after purchasing an additional 1,547 shares during the quarter. Capital Investment Advisors LLC’s holdings in Zoetis were worth $2,426,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ZTS. Webster Bank N. A. boosted its position in Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the period. Quarry LP boosted its holdings in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the period. LRI Investments LLC acquired a new position in Zoetis during the 1st quarter worth $43,000. Hazlett Burt & Watson Inc. increased its holdings in Zoetis by 60.7% during the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after purchasing an additional 102 shares during the period. Finally, Central Valley Advisors LLC acquired a new stake in Zoetis in the 2nd quarter valued at about $49,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 1.2 %

Shares of NYSE ZTS opened at $193.28 on Friday. The business has a 50-day moving average price of $188.98 and a 200 day moving average price of $177.07. The stock has a market cap of $87.57 billion, a PE ratio of 37.82, a price-to-earnings-growth ratio of 3.00 and a beta of 0.89. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company’s revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.41 earnings per share. Equities research analysts forecast that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.89%. Zoetis’s dividend payout ratio is presently 33.86%.

Wall Street Analyst Weigh In

ZTS has been the subject of several recent research reports. Piper Sandler lifted their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research boosted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. increased their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus boosted their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.